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ABSTRACT
BACKGROUND: The objective of the study was to determine the relationship 
between Survivin and Reprimo transcript/protein expression levels, and gastric 
cancer outcome.
METHODS: In silico correlations between an agnostic set of twelve p53-dependent 
apoptosis and cell-cycle genes were explored in the gastric adenocarcinoma TCGA 
database, using cBioPortal. Findings were validated by regression analysis of RNAseq 
data. Separate regression analyses were performed to assess the impact of p53 
status on Survivin and Reprimo. Quantitative reverse-transcription PCR (RT-qPCR) 
and immunohistochemistry confirmed in silico findings on fresh-frozen and paraffin-
embedded gastric cancer tissues, respectively. Wild-type (AGS, SNU-1) and mutated 
p53 (NCI-N87) cell lines transfected with pEGFP-Survivin or pCMV6-Reprimo were 
evaluated by RT-qPCR and Western blotting. Kaplan-Meier method and Long-Rank 
test were used to assess differences in patient outcome.
RESULTS: cBioPortal analysis revealed an inverse correlation between Survivin 
and Reprimo expression (Pearson’s r= -0.3, Spearman’s ρ= -0.55). RNAseq analyses 
confirmed these findings (Spearman’s ρ= -0.37, p<4.2e-09) and revealed p53 
dependence in linear regression models (p<0.05). mRNA and protein levels validated 
these observations in clinical samples (p<0.001). In vitro analysis in cell lines 
demonstrated that increasing Survivin reduced Reprimo, while increasing Reprimo 
reduced Survivin expression, but only did so in p53 wild-type gastric cells (p<0.05). 
Survivin-positive but Reprimo-negative patients displayed shorter overall survival 
rates (p=0.047, Long Rank Test) (HR=0.32; 95%IC: 0.11-0.97; p=0.044).
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CONCLUSIONS: TCGA RNAseq data analysis, evaluation of clinical samples and 
studies in cell lines identified an inverse relationship between Survivin and Reprimo. 
Elevated Survivin and reduced Reprimo protein expression correlated with poor 
patient prognosis in gastric cancer.
INTRODUCTION
Gastric cancer is the third leading cause of cancer-
related deaths worldwide, with 951,000 new cases and 
723,000 deaths in 2012 [1]. In molecular terms, many 
different types of gastric cancer have been described 
and only more recently has a comprehensive molecular 
characterization of primary tumors by The Cancer 
Genome Atlas (TCGA) Research Network [2] begun to 
shed light on this heterogeneity by segregating cases into 
four molecular subtypes: (i) tumors positive for Epstein-
Barr virus (EBV)-associated gastric carcinoma, (ii) 
microsatellite-unstable tumors, (iii) genomically stable 
tumors and (iv) tumors with chromosomal instability [2]. 
Interestingly, genomically stable tumors are enriched for 
Lauren’s class diffuse-type gastric cancer and recurrent 
CDH1, as well as RHOA mutations. On the other hand, 
tumors with chromosomal instability are enriched for 
Lauren’s class intestinal-type gastric cancer, with frequent 
mutations in the tumor protein p53 (TP53), and located at 
the gastroesophageal junction [2]. In gastric cancer, as in 
many cancers, deregulation in the expression of cell cycle 
and apoptosis-related genes, as well as loss of functional 
p53 play an important role in disease development and 
progression. Here, we specifically focused our analysis on 
two cell cycle/apoptosis proteins Survivin (BIRC5) and 
Reprimo (RPRM).
Survivin is a member of the inhibitor-of-apoptosis 
protein (IAP) family (reviewed in Garg et al. [3], 
with multiple physiological and pathological roles 
that are important in development, metabolism, cell 
communication, angiogenesis and motility [4].
The Survivin protein is readily detectable in normal 
gastric mucosa and is proposed there to have a protective 
function, given that infection with H. pylori leads to 
loss of Survivin in the gastric epithelium and increased 
apoptosis in gastric cancer cell lines. Thus, at early stages 
of infection, Survivin aids in the maintenance of gastric 
epithelial integrity. Loss of Survivin due to H. pylori is 
predicted to disrupt gastric mucosa homeostasis and 
contribute significantly to chronic inflammation, which 
then exacerbates signaling pathways that favor disease 
onset and progression [5, 6]. Importantly, however, 
despite early loss of Survivin due to infection, the protein 
is re- or over-expressed in many human cancers and other 
inflammatory diseases [7]. Also, in gastric cancer cells, 
Survivin expression is elevated in tumor samples when 
compared to surrounding normal tissues [8].
Several transcriptional factors have been described 
that recognize the Survivin promoter region and control 
protein expression [9, 10]. Among such transcriptional 
regulators, the tumor suppressor protein p53 was of 
interest because it represses Survivin expression [11], and 
is frequently down-regulated or mutated in cancer [12, 13]. 
Thus, deregulation of p53 may serve to explain, at least in 
part, the observed upregulation of Survivin associated with 
cancer development and progression [14, 15].
Alternatively, RPRM expression promotes cell 
cycle arrest in the G2/M phase and is transcriptionally up-
regulated by p53 [16], in addition to being subject to post-
translational modifications [16–18]. Interestingly, RPRM 
protein expression is reduced in gastric tumor samples 
when compared with non-tumor adjacent mucosa (NTAM) 
[19, 20] and overexpression of RPRM induces apoptosis in 
gastric cancer cells [21]. Indeed, RPRM is now considered 
a novel class II tumor suppressor gene in gastric cancer 
because its expression is silenced by promoter region 
hypermethylation [20], possibly attributable to activity 
of the virulence factor CagA following H. pylori 
infection [22].
Thus, from the available information, both Survivin 
and RPRM emerged as being potentially important in 
gastric cancer, but likely playing essentially opposing 
roles, particularly in controlling G2/M, suggesting also 
that their expression should be mutually exclusive. In 
support of this notion, Survivin and RPRM are suppressed 
or enhanced, respectively, by p53 [11, 16]. Moreover, 
Survivin reportedly also reduces p53 expression [23], 
which, in turn, controls RPRM levels. All together, these 
observations pointed towards the possibility that Survivin 
upregulation, as frequently observed in cancer, may 
contribute to the loss of RPRM.
Since its publication, the TCGA has become a 
powerful tool to interrogate in silico connections between 
genes and pathways altered in cancer and particularly to 
identify patterns of mutual exclusion and/or coexistence 
between genes that are linked to the pathology [24, 25]. 
Thus, we initiated this study in an unbiased manner by 
first interrogating the existence of connections between 
cell cycle and apoptosis in general, and then focusing 
on Survivin and RPRM. Specifically, we sought to 
determine whether Survivin and RPRM expression 
might be mutually exclusive. Initial analysis of RNAseq 
data from the gastric adenocarcinoma TCGA project [2] 
revealed that while for many pairs of cell cycle/apoptosis 
genes co-expression was common, Survivin and RPRM 
were unique because expression was mutually exclusive 
and the connection appeared to be p53 dependent. This 
observation was then validated by PCR analysis in clinical 
samples. Subsequently, we confirmed, with the help of 
gastric cancer cell lines, functionality of the connection 
between Survivin and RPRM. Finally, the clinical 
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significance of the mutual exclusion was evaluated in a 
large data set of gastric cancer cases, where survival rates 
for patients with Survivin positive tumors was found to 
be significantly reduced in those cases where RPRM was 
absent.
RESULTS
Survivin and RPRM expression are inversely 
correlated in a p53-dependent manner as 
determined by analysis of in silico RNAseq data 
from TCGA
We first evaluated available in silico data 
corresponding to an agnostic set of 12 cell-cycle and 
apoptosis-related genes, two major pathways that have 
been linked to gastric cancer [26], from the TCGA 
project [2], using the cBioPortal online platform. Among 
the genes evaluated by cBioPortal [27, 28], positive 
correlations were observed between 5 pairs of genes, while 
an inverse correlation (Pearson’s r = -0.3, Spearman’s 
ρ = -0.55) was only detected between the expression 
levels of the Survivin and RPRM transcripts (see online 
Supplementary Table 2 and Supplementary Figure 1). To 
validate the latter finding, RNAseq data from 237 selected 
gastric cancer patients (selection criteria in methods) from 
the same database were evaluated by linear regression 
models for Survivin and RPRM. Spearman’s analysis 
confirmed a significant negative correlation, indicative of 
mutual exclusion, between Survivin and RPRM transcript 
expression (ρ = -0.37, p<4.2e-09). To evaluate the linear 
relationship between Survivin and RPRM, the following 
linear regression model was proposed:
Survivini= μ + RPRMi + ϵi
where Survivini is the expression level of Survivin 
for subject “i” (in log 2 scale), μ is the overall mean 
expression of Survivin, RPRMi is the coefficient associated 
with the expression level of RPRM (in log 2 scale) for 
subject “i” and ϵi ~ N (0, σ) is the error term. As shown in 
Figure 1A, this model was fit to expression data of these 
two genes.
Next, these samples were segregated according to 
p53 status into mutated or normal (wild-type) p53 groups, 
by the following proposed model:
Survivinis = μ + RPRMi + p53s + RPRMi
* p53s + ϵis
where Survivinis is the expression level of Survivin 
(in log 2 scale) for subject “i” with p53 status “s”, μ is 
the overall mean expression of Survivin, RPRMi is the 
regression coefficient relative to the RPRM expression 
levels (in log 2 scale), p53s is the effect of the p53 subject 
status, RPRMi
* p53s is the interaction effect, and ϵi ~ N 
(0, σ) is the error term. The resulting linear model yields 
statistically significant coefficients for RPRM and their 
interaction with the p53 status and for the interaction 
effect: (RPRMcoefficient = −0.16, p < 0.01) and (RPRM* 
p53wtcoefficient = −0.10, p < 0.05).
These findings imply a highly significant slope 
decrease of at least 1.58-fold in TCGA cases with wild-
type (WT) p53 status when compared to cases with 
mutated p53 status (Figure 1B). In other words, Survivin 
down-regulation by RPRM is 1.58 times stronger in WT 
p53 cases than in mutated p53 cases.
Expression of Survivin and RPRM in clinical 
samples
In order to corroborate our findings from the in silico 
analysis, we evaluated Survivin and RPRM expression in 
biopsies from NTAM and gastric cancer tumor samples. 
Analysis by RT-qPCR revealed that Survivin expression 
was greater in tumors than NTAM (p< 0.001). Conversely, 
RPRM expression was significantly higher in NTAM than 
in tumors (p< 0.0001) (Figure 2). These findings were 
confirmed at the protein level by immunohistochemical 
analysis of similar samples (see online Supplementary 
Figure 3).
Survivin overexpression in cell lines reduces 
RPRM expression
To determine the effects of Survivin on RPRM 
expression, three gastric cancer cell lines were transfected 
with a plasmid encoding Survivin. As expected, for all 
cell lines a significant increase in Survivin transcript 
(p< 0.05) and protein expression levels was detectable 
24h post-transfection (Figure 3). Alternatively, RPRM 
mRNA expression levels in SNU-1 cells 24h after 
transfection with pEGFP-Survivin were considerably 
reduced as compared with the pEGFP-empty transfected 
cells (p< 0.05) (Figure 3A). Additionally, to restore 
RPRM in AGS cells, where expression is suppressed by 
promoter methylation, we treated the cells with 5’-Aza, 
an inhibitor of DNA methyl transferases (see online 
Supplementary Figure 4). Also in this case, we observed 
that overexpression of Survivin using the pEGFP-Survivin 
plasmid reduced RPRM expression significantly (p< 
0.05) in comparison to the pEGFP-empty cells (Figure 
3B). Conversely, there were no statistically significant 
differences in RPRM transcript expression between 
NCI-N87 cells transfected with the plasmid encoding 
Survivin or empty plasmid (Figure 3C). Also, we 
transfected HEK-293T cells with pEGFP-Survivin as a 
normal control. Surprisingly, relative RPRM mRNA levels 
increased rather than decreased upon Survivin expression 
in these cells (see Supplementary Figure 5A).
RPRM overexpression reduces Survivin 
expression
To confirm the mutual exclusivity hypothesis 
between Survivin and RPRM, we also increased RPRM 
expression levels by transiently transfecting with pCMV6-
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RPRM. As expected, for all cell lines a significant increase 
in RPRM transcript (p< 0.05) and protein expression 
levels (p< 0.05) were detected 24h post-transfection 
(Figure 4). Survivin mRNA expression levels significantly 
diminished in SNU-1 cells transfected with plasmid 
encoding RPRM as compared with the empty plasmid (p< 
0.05) (Figure 4A). Also, RPRM overexpression in AGS 
cells significantly reduced Survivin expression levels (p< 
0.05) as compared with pCMV6-empty vector (Figure 
4B). Conversely, there were no statistically significant 
differences in Survivin mRNA expression levels in 
transfected NCI-N87 cells overexpressing or not RPRM 
(Figure 4C). On the other hand, when HEK-293T cells 
were transfected with pCMV6-RPRM as a normal control, 
Figure 1: Analysis of Survivin and RPRM transcript expression in gastric cancer samples from the TCGA database. 
(A) Linear regression model for Survivin and RPRM in 237 cases for which Survivin and RPRM counts were greater than zero and p53 
status was available. log2(Survivin) = 8.98 − 0.20 * log2(RPRM) (B) Linear regression models for Survivin and RPRM according to p53 
status. For p53-mutated samples (n=116, red regression line): log2(Survivin) = 9.02106 − 0.10055 * log2(RPRM) For wild-type p53 samples 
(n=121, blue regression line): log2(Survivin) = 8.87772 − 0.26013 * log2(RPRM).
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Survivin mRNA levels remained essentially unchanged 
(see online Supplementary Figure 5B).
To investigate whether RPRM overexpression 
altered Survivin protein levels in the cells, we analyzed 
extracts from pCMV6-RPRM and pCMV6-empty 
transfected cells by western blotting. The analysis 
revealed a noticeable, but statistically insignificant 
decrease in Survivin protein levels in SNU-1 cells (Figure 
4D). Alternatively, in AGS cells, a significant decrease 
in Survivin expression levels was observed following 
transfection within pCMV6-RPRM as compared with the 
control pCMV6-empty vector transfected cells (p<0.05) 
(Figure 4E). Conversely, when we overexpressed RPRM 
in NCI-N87 cells, no statistically significant differences 
in Survivin protein levels were observed as compared 
with empty plasmid control cells (Figure 4F). On the 
other hand, when HEK-293T cells (normal control) were 
transfected with pCMV6-RPRM, Survivin protein levels 
increased (see online Supplementary Figure 5C).
Clinical significance of Survivin and RPRM 
expression in gastric cancer
To explore the possible clinical significance of 
the mutual exclusion between Survivin and RPRM, a 
TMA containing 114 cases was immunohistochemically 
evaluated for expression of both proteins and correlated 
with clinicopathological variables, as well as overall 
survival. As shown in Figure 5, among the 107 available 
cases, Survivin protein expression was found in 47.6% 
(57/107) of cases (>10% staining). On the other hand, 
RPRM protein was expressed in 38.3% (41/107) of cases 
(>20% staining). To evaluate the clinicopathological 
significance of these findings, cases adjusted by age and 
sex were compared. Overall, no associations were found 
(data not shown). However, a worse prognosis among 
Survivin-positive / RPRM-negative cases was detected 
(p=0.047, Long Rank Test) (HR=0.32; 95%IC: 0.11-0.97; 
p=0.044) (Figure 6).
DISCUSSION
Deregulation of p53-mediated cellular processes, 
such as apoptosis and cell cycle control signaling 
pathways, have been associated with the progression of 
gastric cancer [12, 26, 29, 30]. In the current study, the 
TCGA database was interrogated to identify deregulated 
p53-associated cell cycle and apoptosis genes in gastric 
cancer. In doing so, the pair Survivin and RPRM stood 
out because a highly significant negative correlation was 
detected between the two genes at the mRNA level. In 
functional terms, given that both genes regulate cell cycle 
Figure 2: Analysis of Survivin and RPRM mRNA levels in paired tissue samples from primary tumors and non-
tumor adjacent mucosa (NTAM) from gastric cancer cases. Survivin and RPRM expression levels were evaluated by RT-qPCR 
in biopsies of tissue samples and normalized to RPS13 mRNA expression levels. Statistically significant differences between RPRM 
expression in NTAM and tumor samples (**p≤ 0.001), as well as for Survivin expression in NTAM and tumor samples (****p≤ 0.0001) are 
indicated (means ± SEM; n = 13 for each sample type).
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Figure 3: Overexpression of Survivin reduces RPRM mRNA levels in gastric cancer cell lines. Survivin and RPRM mRNA 
expression levels were evaluated by RT-qPCR. Results for (A) SNU-1, (B) AGS and (C) NCI-N87 cells 24 h after transfection with pEGFP-
Survivin or pEGFP-empty are shown after normalizing to β-actin mRNA expression levels used as a housekeeping control gene. Note that 
AGS cells were treated with 5-Aza-2’-deoxycytidine (1 mM) for 24 h prior to transfection. Expression levels in non-transfected cells were 
used to standardize each experiment (control). Statistically significant differences compared to cells transfected with pEGFP-Survivin or 
empty vector are shown (means ± SEM; n = 4; Mann-Whitney test; *p< 0.05).
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Figure 4: Overexpression of RPRM reduces Survivin levels in gastric cancer cell lines. Survivin and RPRM expression levels 
were evaluated by RT-qPCR in (A) SNU-1, (B) AGS and (C) NCI-N87 cells 24 h after transfection with either pCMV6-empty or pCMV6-
RPRM. Values were normalized to β-actin mRNA expression levels used as a housekeeping gene. Expression levels in non-transfected cells 
were used to standardize each experiment (control). Protein levels assessed by Western blot analysis for (Continued)
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Figure 4: (Continued) Overexpression of RPRM reduces Survivin levels in gastric cancer cell lines. (D) SNU-1, (E) 
AGS and (F) NCI-N87 cells 24 h after transfection with empty vector or pCMV6-RPRM normalized to β-actin are shown. Statistically 
significant differences compared to cells transfected with pCMV6-RPRM or empty plasmid are indicated (means ± SEM; n = 4; Mann-
Whitney test; *p≤ 0.05).
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progression in opposing ways at the G2/M transition [24, 
31], this negative correlation was considered potentially 
relevant to gastric cancer development. Thus, we then 
validated these findings at the RNA and protein levels 
in clinical samples from gastric cancer patients. We 
also corroborated these findings in gastric cell lines by 
showing that Survivin overexpression suppressed RPRM 
and conversely RPRM overexpression reduced Survivin 
levels. Of note, we observed significant down-regulation 
only in cells expressing wild-type p53, but not in cells 
with mutated p53. These results are consistent with the 
initial in silico analysis of TCGA data, where the negative 
correlation between Survivin and RPRM expression 
was notably accentuated in patients with wild-type p53 
protein. The clinical significance of these findings was 
underscored by showing that survival rates of Survivin-
positive gastric cancer patients was significantly reduced 
when RPRM expression is lost.
Survivin is poorly expressed in the G1 phase, 
increases by 6-fold in the S phase and by more than 40-
fold in G2/M phase of the cell cycle (reviewed in Jaiswal 
et al., [32]. Thus, the presence of Survivin favors G2/M 
progression, cell survival and proliferation, all functions 
diametrically opposed to the documented role of RPRM. 
Figure 5: Analysis of Survivin and RPRM protein expression levels in a tissue microarray containing gastric cancer 
cases. Survivin and RPRM expression levels evaluated by immunohistochemistry on a tissue microarray of gastric cancer cases for 
clinicopathological correlations. Survivin and RPRM presence in cells is revealed as brown staining. All samples were counterstained with 
hematoxylin (blue nuclei). The original magnification for images (A-D) and (a-d) was 100x (image at bottom right) and 400x for images 
(A’-D’) and (a’-d’). The scale bar setting for all images was 100 μm. Survivin and RPRM protein levels were semi-quantified using the 
median expression method (see methods for details) in TMA sections. Two cases did not show mutual Survivin and RPRM exclusion, being 
negative (A-a) or positive (D-d) for both genes. B-b and C-c show mutual exclusion for Survivin and RPRM, being either Survivin(-)/
RPRM(+) or Survivin(+)/RPRM(-).
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Given that p53 favors RPRM expression, the fact that 
Survivin reportedly also reduces p53 expression [4, 23] 
could explain how Survivin controls RPRM in a p53-
dependent manner, as indicated by our results (Figure 3).
PI3K/Akt activity is known to favor the expression 
of Survivin in VEGF-stimulated endothelial cells and 
contribute thereby to cell survival and angiogenesis 
[33]. More recently, Survivin expression in cancer cells 
was linked to activation of the PI3K/Akt/beta-catenin/
Tcf-Lef pathway, to increase VEGF expression by these 
cells and promote angiogenesis. Therefore, in doing 
so, Survivin expression in cancer cells participates in a 
positive feedback amplification loop, that augments PI3K/
Akt activity, promotes VEGF liberation, angiogenesis 
and tumorigenesis [34–36]. Given the importance of p53 
loss in gastric cancer progression, the fact that PI3K/
Akt activity directly favors p53 down-regulation by 
promoting Mdm2–mediated proteasomal degradation [37] 
posits enhanced Survivin expression as a potentially key 
determinant in gastric cancer progression by generating 
a feedback amplification loop that would not only 
promote PI3K/Akt activity, but also favor the loss of p53 
and RPRM. While highly intriguing, further studies are 
required to substantiate this possibility.
In contrast to Survivin, little information is available 
concerning RPRM regulation and activity. RPRM induces 
cell cycle arrest at the G2/M phase and RPRM expression 
is enhanced by p53 upon exposure to DNA damage [16]. 
Functional assays, such as colony formation and anchorage-
independent growth assays, point towards a putative tumor 
suppressor role for RPRM in gastric cancer cells [20]. In 
addition, epigenetic silencing of the RPRM gene by promoter 
methylation is associated with loss of RPRM expression in 
gastric cancer cells [38]. Accordingly, RPRM is often lost 
in invasive stages of gastric cancer [20]. For these reasons, 
in our experiments, we also used the demethylating agent 
5’-azacytidine to restore RPRM expression in AGS cells. 
When we transfected these cells with pEGFP-Survivin a 
significant decrease in RPRM was observed (Figure 3B). 
Unfortunately, however, the transfection with empty-
Figure 6: Analysis of overall survival curves among Survivin positive cases according to RPRM protein expression 
levels. Results are shown comparing 21 Survivin positive/RPRM positive and 17 Survivin positive/RPRM negative cases. Overall survival 
analysis by Kaplan-Meier estimation considering Survivin and RPRM protein expression after correction for age and sex. A worse prognosis 
among Survivin-positive patients is observed in RPRM negative cases (p=0.047, Long Rank Test) (HR=0.32; 95%IC: 0.11-0.97; p=0.044).
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vector also had a substantial effect on RPRM expression. 
This represents a limitation to our study, perhaps reflecting 
the poor specificity of the demethylating agent. Recently, 
reprogrammed re-expression of RPRM by CRISPR/dCas9 
system was reported to induce beneficial effects in the 
AGS cell line [21]. This could represent a useful tool to 
specifically restore RPRM expression in these cells in future 
studies. Nonetheless, our results in SNU-1 cells (Figure 4A) 
indicate that overexpression of RPRM sufficed to reduce 
Survivin expression, and that p53 was required because 
such RPRM-induced changes were not seen in p53-deficient 
NCI-N87 cells (see Figure 3C). In gastric cell lines, we 
also corroborated these findings by showing that Survivin 
overexpression suppressed RPRM and conversely RPRM 
overexpression reduced Survivin. Of note, we observed 
significant down-regulation only in cells expressing wild-
type p53, but not in cells with mutated p53 (see results 
with NCI-N87 cells, Figures 3C and 4C). These results are 
consistent with the initial results obtained by in silico analysis 
of the TCGA data, where the inverse correlation between 
Survivin and RPRM expression was highly accentuated in 
patients with wild-type p53 protein (Figure 1).
These observations mentioned above indicate that 
loss of RPRM by promoter region methylation could 
favor disease progression by augmenting Survivin. 
Accordingly, our results concerning Survivin and RPRM 
protein expression in a large set of clinical samples 
validate these in vitro findings by revealing substantially 
diminished 5-year survival among the paired Survivin-
positive/RPRM-negative gastric cancer cases (Figure 6). 
Taken together, these findings not only confirm at the 
clinical level the inverse correlation between Survivin and 
RPRM expression, but also identify a protective effect 
and enhanced survival for those Survivin positive-gastric 
cancer cases in which RPRM is co-expressed.
Clearly, further research will be required to shed 
light on the detailed molecular mechanisms and signaling 
pathways linking Survivin and RPRM regulation to one 
another, as well as the therapeutic potential that may be 
derived from such insight.
MATERIALS AND METHODS
In silico analysis of TCGA RNAseq data
An initial exploratory analysis was performed 
on data from the stomach adenocarcinoma (STAD) 
TCGA [2] using the online cBioPortal for Cancer 
Genomics platform (http://www.cbioportal.org) [27, 
39]. A total of 258 cases were selected, corresponding 
to the “All Complete Tumors” option of the Stomach 
Adenocarcinoma “TCGA, Nature” tab from cBioPortal 
(see online Supplementary Table 1). Given our interest 
in analyzing the correlation between cell cycle and 
apoptosis, Pearson’s and Spearman’s correlation values 
were retrieved using the “Co-expression” tab from the 
cBioPortal for an agnostic set of twelve p53-dependent 
apoptosis- and cell cycle- related genes (see online 
Supplementary Table 2 and Supplementary Figure 1). 
Subsequently, RNAseqV2 data from all tumor samples 
available from the STAD TCGA were downloaded 
using the DownloadRNASeqData function included in 
Module_A from TCGA-Assembler [40], on R statistical 
programming language. Data were processed using the 
ProcessRNASeqData function included in Module_B from 
TCGA-Assembler (see online Supplementary Figure 2). 
Of these, 237 cases met the following criteria: i) Survivin 
and RPRM expression were both greater than 0, and ii) 
p53 mutational status information (mutated p53 n=116 
and wild-type p53 n=121) was available on cBioPortal 
(see online Supplementary Table 3). The p53 status was 
manually retrieved from cBioPortal and cross-referenced 
to the RNAseq expression matrix using the unique TCGA 
identifiers (barcode) for each case. For R code, see 
Supplementary Material.
Clinical samples
Thirteen de-identified matched tumor and NTAM 
fresh-frozen human tissue samples obtained from upper 
gastrointestinal endoscopic procedures at the Instituto 
Chileno-Japones de Enfermedades Digestivas – Hospital 
Clinico San Borja-Arriaran (ICHJED-HCSBA) were 
evaluated for Survivin and RPRM expression by 
quantitative reverse transcription PCR (RT-qPCR). 
Eighteen de-identified matched tumor and NTAM 
formalin-fixed and paraffin-embedded samples from 
the pathology archives at the ICHJED-HCSBA were 
selected for the immunohistochemical evaluation of 
Survivin and RPRM expression. A previously reported 
TMA cohort of 114 consecutive gastric cancer cases 
[20, 41], stratified according to the WHO Classification 
of Gastric Cancer, the Japanese Research Society for 
Gastric Cancer recommendations and the AJCC gastric 
cancer staging system [18, 42, 43] with a 12 year follow-
up [44], was evaluated for the clinical significance of the 
mutual exclusion between Survivin and RPRM. All cases 
selected from the pathology archives of the ICHJED-
HCSBA had undergone subtotal or total gastrectomy as 
the only treatment [44]. Clinico-pathological correlations, 
but not follow-up survival, have been reported for RPRM 
in these cases [20]. Written informed consent was obtained 
from each participant and protocols were approved by the 
Ethics Committee of the Pontificia Universidad Católica 
de Chile and ICHJED-HCSBA.
Quantitative reverse transcription polymerase 
chain reaction (RT-qPCR)
Total RNA was isolated with TriZOL™ (Life 
Technologies, Carlsbad, CA, US) according to 
manufacturer’s instructions and then used as a template 
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to synthesize first-strand complementary DNAs (cDNA) 
by reverse-transcription PCR with Oligo dT primers 
(Promega, Madison, WI, US) and Moloney Murine 
Leukemia Virus reverse transcriptase (Promega, Madison, 
WI, US). The cDNA was amplified by RT-qPCR using 
5x HOT FIREPol Evagreen® qPCR Mix Plus (Solis 
Biodyne, Riia, Tartu, Estonia) according to manufacturer’s 
instructions with the following primer pairs: for Survivin, 
sense primer 5′-CTGGCAGCCCTTTCTCAAGGA-3′ and 
anti-sense primer 5′-GCAACCGGACGAATGCTTTT-3′; 
for RPRM, sense primer 5′-GAGCGTAGCCTGTACATAA 
TGC-3′ and anti-sense primer 5′-CCTTCACGAGGAAG 
TTGATCAT-3′; for beta-actin, sense primer 5′-AAAT 
CGTGCGTGACATTAAGC-3′ and anti-sense primer 
5′-CCGATCCACACGGAGTACTT-3′; for RPS13, sense 
primer 5′-CTCTCCTTTCGTTGCCTGAT-3′ and anti-
sense primer 5′-TGAAGGAGTAAGGCCCTTCT-3′. All 
reaction products were analyzed after 40-45 amplification 
cycles with the following thermal profile: activation 1s at 
25°C and 10min at 95°C, denaturation 15s at 95°C, 30 
s at 98°C, annealing 18s at 72°C and extension 15s at 
95°C, 1s at 25°C, 15s at 70°C and 1s at 95°C. Relative 
fold-increases in gene expression levels were calculated 
using the MIQE (minimum information for publication 
of quantitative real-time PCR experiments) guidelines 
[45]. Survivin and RPRM expression was normalized 
to transcript levels of the RPS13 housekeeping gene for 
biopsy specimens and then expressed relative to values 
obtained for NTAM samples. Alternatively, values 
obtained for cell lines were standardized to beta-actin 
as a housekeeping gene and then expressed relative to 
expression obtained for wild-type cell extracts (control) in 
each transfection condition (value = 1).
Immunohistochemistry
Survivin and RPRM protein expression levels 
were evaluated using formalin-fixed and paraffin-
embedded tissue samples. Survivin and RPRM were 
detected using the Vectastain Elite Kit R.T.U (Vector 
Laboratories, Ingold Road, CA, US), according to the 
manufacturer’s instructions, with a polyclonal anti-
Survivin antibody (R&D Systems, Minneapolis, MN, 
USA) and a polyclonal anti-RPRM antibody (Sigma, St 
Louis, MO, US) [6, 20]. Results of TMA immunostaining 
were considered positive based on the median of 
protein expression. In the case of RPRM, the median 
of cytoplasmic expression in epithelial cells was 20%. 
In the case of Survivin median expression of nuclear 
staining was 10%. Stained tissue sections were evaluated 
by two independent pathologists (GCA and AHC) who 
were unaware of the clinical data. Supplementary results 
of whole block immunostaining for NTAM and tumor 
tissues were evaluated using Quick Score (Q Score) 
analysis as described [46].
Cell lines and culture conditions
The gastric cancer cell lines AGS (ATCC CRL 
1793), SNU-1 (ATCC CRL 5971) and NCI-N87 (ATCC 
CRL 5822) were cultured in Roswell Park Memorial 
Institute 1640 medium (Gibco BRL, Carlsbad, CA, USA). 
The human embryonic kidney cell line HEK293T (ATCC 
CRL 3216) was cultured in Dulbecco’s modified Eagle 
medium (Gibco BRL, Carlsbad, CA, USA). According to 
data sheet information provided by ATCC, all cells used 
here have the p53 wild-type gene, except for NCI-N87 
cells, where the p53 gene is mutated. In all cases, culture 
media were supplemented with 10% fetal bovine serum 
(Biological Industries, Sebethe Drive, Cromwell, CT, 
US) and antibiotics (10,000 U/ml penicillin and 10 mg/
ml streptomycin), and cells were cultured at 37°C in a 
humidified atmosphere containing 5% CO2.
Transfections
SNU-1, AGS, NCI-N87 and HEK293T cells 
(3×10-5 in each case) were transfected in 6-well plates 
with pEGFP-empty, pEGFP-Survivin or pCMV6-empty, 
pCMV6-RPRM (tagged with FLAG)[6, 20] using the 
ViaFect™ Transfection Reagent (Promega, Madison, 
WI, US) according to manufacturer’s instructions. Prior 
to transfection with pEGFP-empty and pEGFP-Survivin, 
AGS cells were treated with the demethylating agent 
5’-Aza-2’-deoxycytidine (5’-Aza) at a concentration of 1 
μM for 24 h in order to revert epigenetic RPRM silencing 
via promoter methylation [20].
Western blot analysis
Cells were harvested and whole-cell lysates were 
prepared by sonicating in buffer (NP-40 and SDS 10%), 
supplemented with a protease and phosphatase inhibitor 
cocktail (Sigma Aldrich, St Louis, MO, US). Protein 
concentrations were determined using the BCA Protein 
Assay reagent (Pierce, Thermo Scientific, Logan, Utah, 
USA) according to the manufacturer's instructions. 
Equal amounts of total cellular protein (50ug/lane) were 
separated by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis on 12% acrylamide minigels (Bio-
Rad Laboratories, Hercules, CA, US) and transferred to 
nitrocellulose membranes (Amersham™Protran™0.45μm, 
Life Science, Sigma, St Louis, MO, US). The membranes 
were blocked as described previously [34] and then probed 
with rabbit anti-beta-actin polyclonal antibody (1:5000, 
A5060, Sigma, St Louis, MO, US) as a loading control, 
mouse anti-FLAG monoclonal antibody (1:2000, F3165, 
Sigma, St Louis, MO, US) or rabbit anti-human Survivin 
polyclonal antibody (1:3000, AF886, R&D Systems, 
Minneapolis, MN, USA). Horseradish peroxidase-
conjugated anti-rabbit (1:3000, AP132P, Millipore, Merck, 
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Darmstadt, Germany) or anti-mouse secondary antibodies 
(1:3000, 1706516, Bio-Rad Laboratories, Hercules, CA, 
US) were used to detect primary antibodies with the 
EZ-ECL system (Biological Industries, Sebethe Drive, 
Cromwell, CT, US) according to the manufacturer's 
protocol. Western blots were used to quantify protein levels 
by scanning densitometry as described previously [28].
Statistical analysis
Downloaded RNAseqV2 data were statistically 
evaluated by Spearman correlation and linear regression 
analysis using the R statistical programming environment. 
Data from cell lines and clinical samples were compared 
pairwise between cells transfected with empty plasmid 
or plasmid encoding the indicated insert sequence, and 
NTAM or tumor samples, respectively. Values were 
analyzed using the Mann-Whitney test and GraphPad 
Prism software (version 6.0, San Diego, CA, US). All data 
were obtained from 3 or more independent experiments 
and were expressed as mean ± SEM. Clinicopathological 
and overall survival were determined by the Kaplan-
Meier test. Differences between survival rates were 
assessed using the Long-Rank test. All calculations were 
performed by STATA v14,0. A p value of less than 0.05 
was considered statistically significant [47].
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